Haleon Plc slid the most in nearly one year after sales grew less than expected in 2025, as a weak cold and flu season meant fewer customers purchased its over-the-counter medicines. The London-listed company reported disappointing revenue figures that fell short of analyst forecasts, triggering a sharp decline in its share price. This performance underscores the vulnerability of consumer health companies to seasonal fluctuations, particularly those reliant on winter remedies. Haleon's 2025 sales growth lagged behind expectations, a trend that could pressure its full-year earnings guidance and shareholder confidence. The company's over-the-counter portfolio, including brands like Nurofen and Strepsils, faces headwinds from reduced demand during a milder-than-usual flu period. Investors reacted swiftly to the news, with Haleon shares dropping nearly 5% in early trading, reflecting concerns about near-term revenue sustainability. This seasonal weakness may prompt the company to reassess its product mix or marketing strategies for 2026. The stock's sharp decline highlights how external factors like weather patterns can significantly impact pharmaceutical sales cycles, a risk factor investors now view as more pronounced than previously assumed.